Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

INSM - Insmed - Deel 15

2.002 Posts
Pagina: «« 1 ... 38 39 40 41 42 ... 101 »» | Laatste | Omlaag ↓
  2. [verwijderd] 11 juli 2007 22:03

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Laatste 0,80
    Laatste volume 1.000
    Tijd 21:59
    +/- 0,01 1,15%
    Volume 637.025

    Bied
    Biedvolume
    Laat
    Laatvolume

    Slot 0,79 10/7
    Open 0,78 15:30
    Hoog 0,81 16:09
    Laag 0,78 15:30
  3. ludwig mack 12 juli 2007 12:39

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    the wall street journal van heden, met dank aan camobs:



    House Acts to Boost FDA Powers; Biotech Fight Looms
    By ANNA WILDE MATHEWS
    July 12, 2007; Page A2

    WASHINGTON -- The House passed legislation that would bolster the powers of the Food and Drug Administration, but the vote sets up a confrontation with the Senate over whether to create a pathway for generic versions of biotechnology drugs.

    The House FDA bill, approved 403-16, mostly parallels a bill that passed the Senate in May. Both versions would devote more money to monitoring the safety of marketed drugs and increase the agency's authority over medications that raise safety concerns. The agency would have the clear ability to order follow-up studies, restrict distribution and enforce changes to the medications' labels. The bills don't grant the FDA the power to force a moratorium on direct-to-consumer advertising, a tough restriction that was discussed earlier, though the agency would be able to levy fines for false and misleading promotions.


    A compromise version of the two measures is expected to be completed in the next few months -- perhaps before the August recess -- because the legislation renews industry fees that fund much of the FDA's work. Both the House and Senate versions would also force drug companies to make public information from many clinical trials.

    But there is a key divide between the Senate and House bills: the Senate will include language that creates a pathway for the FDA to approve copycat versions of biotech drugs, and the House bill doesn't address the issue. The Senate provisions reflect an agreement among a group of key senators including Democrat Edward Kennedy of Massachusetts and Republican Michael Enzi of Wyoming, the health-committee leaders.

    Mr. Kennedy has said he will introduce that compromise, which was reached after the Senate passed its FDA bill, as part of the proceedings of the bicameral conference committee that will resolve differences between the House and Senate proposals.

    A key question is whether House leaders, including Energy and Commerce Committee Chairman John Dingell, a Michigan Democrat, will be willing to accept the move. Different House members have introduced divergent bills, but the Energy and Commerce Committee hasn't moved forward with any of them.

    In an interview yesterday, Mr. Dingell signaled that he will oppose inclusion of the copycat biotech-drug language in a final bill. He said he supports a pathway for such drugs, but has safety concerns as well as questions about whether science is advanced enough to verify a copy's similarity to the original medication. "There's really no record to justify that kind of action" in the House, which hasn't yet fully debated a bill, he said.

    The issue is extremely important for the generics and biotech industries, and it has been the focus of extensive lobbying. Currently, the FDA doesn't have the power to approve generic versions of most biotech drugs, which have become some of the most important, and expensive, treatments. Generics makers will prod for inclusion of the Senate generic-biotech language. Biotech makers, though, are expected to push for the House to consider its own bill, which could stall the change.

    A spokesman for the Biotechnology Industry Organization said "it's a complex issue, and it deserves full and deliberate consideration."

    A spokeswoman for the Generic Pharmaceutical Association said in an email that the group is "cautiously optimistic" that the copycat-biotech provisions will be in the final FDA legislation.

  4. [verwijderd] 12 juli 2007 13:59

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    In het kader van...Hoe manipuleer ik mijn aandeel als CEO, een stukje uit de WSJ van vandaag.
    Dan vraag je je toch af: " Wie is die Read_this_now precies?", die en zo actief is op YMB, alsook moderator op Ihub...Hm?...Of Coinstarz, of Mpetisch.
    online.wsj.com/article/SB118418782959...

    PAGE ONE

    Whole Foods Is Hot,
    Wild Oats a Dud --

    So Said 'Rahodeb'
    Then Again, Yahoo Poster
    Was a Whole Foods Staffer,
    The CEO to Be Precise
    By DAVID KESMODEL and JOHN R. WILKE
    July 12, 2007; Page A1

    In January 2005, someone using the name "Rahodeb" went online to a Yahoo stock-market forum and posted this opinion: No company would want to buy Wild Oats Markets Inc., a natural-foods grocer, at its price then of about $8 a share.

    "Would Whole Foods buy OATS?" Rahodeb asked, using Wild Oats' stock symbol. "Almost surely not at current prices. What would they gain? OATS locations are too small." Rahodeb speculated that Wild Oats eventually would be sold after sliding into bankruptcy or when its stock fell below $5. A month later, Rahodeb wrote that Wild Oats management "clearly doesn't know what it is doing .... OATS has no value and no future."

    The comments were typical of banter on Internet message boards for stocks, but the writer's identity was anything but. Rahodeb was an online pseudonym of John Mackey, co-founder and chief executive of Whole Foods Market Inc. Earlier this year, his company agreed to buy Wild Oats for $565 million, or $18.50 a share.

    For about eight years until last August, the company confirms, Mr. Mackey posted numerous messages on Yahoo Finance stock forums as Rahodeb. It's an anagram of Deborah, Mr. Mackey's wife's name. Rahodeb cheered Whole Foods' financial results, trumpeted his gains on the stock and bashed Wild Oats. Rahodeb even defended Mr. Mackey's haircut when another user poked fun at a photo in the annual report. "I like Mackey's haircut," Rahodeb said. "I think he looks cute!"

    Mr. Mackey's online alter ego came to light in a document made public late Tuesday by the Federal Trade Commission in its lawsuit seeking to block the Wild Oats takeover on antitrust grounds. Submitted under seal when the suit was filed in June, the filing included a quotation from the Yahoo site. An FTC footnote said, "As here, Mr. Mackey often posted to Internet sites pseudonymously, often using the name Rahodeb."

    After The Wall Street Journal contacted Whole Foods yesterday, the company said in a statement that among millions of documents it gave the FTC were postings its CEO made from 1999 to 2006 "under an alias to avoid having his comments associated with the Company and to avoid others placing too much emphasis on his remarks." The statement said, "Many of the opinions expressed in these postings now have far less relevance than when they were written." Whole Foods didn't confirm every Rahodeb posting as being from Mr. Mackey.

    Mr. Mackey declined to be interviewed. But he soon posted on the company Web site, saying that the FTC was quoting Rahodeb "to embarrass both me and Whole Foods." He also said: "I posted on Yahoo! under a pseudonym because I had fun doing it. Many people post on bulletin boards using pseudonyms." He said that "I never intended any of those postings to be identified with me."

    Mr. Mackey's post continued: "The views articulated by rahodeb sometimes represent what I actually believed and sometimes they didn't. Sometimes I simply played 'devil's advocate' for the sheer fun of arguing. Anyone who knows me realizes that I frequently do this in person, too."
    [More] RAHODEB SPEAKS

    Postings by 'Rahodeb' on Yahoo:
    • Rahodeb's farewell comment to the Yahoo message board for Whole Foods stock in August 2006.
    • Rahodeb says the fundamentals of Wild Oats shares haven't improved and that its stock price had risen merely because of speculation of a buyout.
    • Rahodeb lambastes a Yahoo user who claimed Wild Oats had been a takeover target at $14 to $16 a share.
    • Rahodeb predicts that Whole Foods shares will one day trade at more than $800.
    • Rahodeb claims Whole Foods shares are undervalued and Wild Oats is overvalued.
    Note: Whole Foods didn't authenticate each and every one of Rahodeb's postings as being from Mr. Mackey. But the company and Mr. Mackey confirmed that he made numerous postings under the name Rahodeb from 1999 to 2006.

    Like Whole Foods itself, Mr. Mackey, a 53-year-old vegan, is somewhat unconventional. He dropped out of college and worked at a natural-foods store before co-founding Whole Foods in Austin, Texas, in 1980. He and his wife practice yoga and meditation and own a 720-acre ranch west of Austin. He once took a sabbatical to hike the Appalachian Trail.

    He built Whole Foods in part by acquiring many smaller chains. In January, he slashed his salary to $1, saying, "this is what my heart is telling me is the appropriate thing to do right now."

    Whole Foods agreed this February to acquire Wild Oats, of Boulder, Colo. The FTC sued in federal court in Washington to block the deal, saying it would reduce competition. The agency is trying to use Mr. Mackey's own words against him. Its suit quotes the CEO as telling other board members the takeover would enable Whole Foods "to avoid nasty price wars" and reduce the risk that a big conventional grocer would create a competitor to Whole Foods.

    When that part of the suit became public, Mr. Mackey fired back with a 14,000-word treatise on his blog on the Whole Foods Web site. He accused the government of "bullying tactics," failing to do its homework and taking out of context "macho posturing" by executives that's common.

    Rahodeb had begun posting on Yahoo Finance in the late 1990s, and quickly became known as a cheerleader for Whole Foods stock. "I admit to my bias," he wrote in 2000. "I love the company and I'm in for the long haul. I shop at Whole Foods. I own a great deal of its stock. I'm aligned with the mission and values of the company ... Is there something wrong with this?"

    Rahodeb expressed pride in the CEO's work. "While I'm not a 'Mackey groupie,'" he wrote in 2000, "I do admire what the man has accomplished."

    By 2005, Whole Foods' $4 billion in annual sales made it the leading player in natural and organic foods. In January of that year, with the stock at a split-adjusted price of about $47, Rahodeb predicted great things: "13 years from now Whole Foods will be a $800+ stock before splits." The stock closed yesterday at $39.50.

    For an executive to use a pseudonym to praise his company and stock "isn't per se unlawful, but it's dicey," said Harvey Pitt, a former Securities and Exchange Commission chairman. Told of the Mackey posts, Mr. Pitt said, "It's clear that he is trying to influence people's views and the stock price, and if anything is inaccurate or selectively disclosed he would indeed be violating the law." He added that "at a minimum, it's bizarre and ill-advised, even if it isn't illegal."

    A spokeswoman for Whole Foods said Mr. Mackey only revealed information about Whole Foods that already was public knowledge. His comments "weren't illegal" and weren't "against company policy," she said.

    Rahodeb sometimes sparred with other users. "Your quarterly cash flow variance isn't statistically meaningful because the time period is too short," he told a user who criticized Whole Foods in March 2006. Rahodeb then pasted a summary of the previous six years of the company
  5. [verwijderd] 12 juli 2007 14:57

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Uit CC van 08:30.

    Developing Biogenerics for:

    Neupogen ($976m verkopen)
    Neulasta ($2.9b verkopen)
    Betaseron ($482m verkopen)
    Epogen ($3.2b verkopen)
    Avonex/Rebif ($1.7b verkopen)
    Humatrope ($400m verkopen)

    Bijna 9 miljard aan jaarlijkse verkopen voor deze medicijnen die INSMED denkt te gaan produceren.

    Ph III te starten in Q4 2007 voor HARS & MMD.

    Partner is gepland voor Q4 2007.

    Geluk, F.
  6. ludwig mack 12 juli 2007 15:07

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    ja, iedere fanaticus heeft wel een eigen agenda ........
    het is bekend dat sommige betaald worden of de fora te beinvloeden en dat heb ik ook wel eens vermoed .......; een keer hebben we toch een ontmaskerd, die gaf toch toe hij voor een broker werkte, hier op de nedl. site van de iex ....., wellicht betaalt door amerikanen.
    gr
  8. [verwijderd] 12 juli 2007 15:37

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    marieke2 schreef:

    Denk niet dat de koers hier hard gaat op reageren.
    ...Dat is het mooie juist!...Tot einde van Q3 zal de PPS waarschijnlijk alleen maar dalen, want geen nieuws of updates...hooguit speculaties!

    Het geeft ons de mogelijkheid om tegen mooie lage koersen bij te kopen...dat't gaat komen is zeker...alleen de tijdshorizon is iets langer.

    Geluk, F.
    (M'n dochter kraaide van plezier bij't horen van zoveel mooie 'nieuws' in de CC)
  10. [verwijderd] 12 juli 2007 16:09

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0


    Re: U.S. House fails to act on biogenerics bill:-wait till next year !
    The Political climate will be better.Election time for most of Congress.

    FDA bill approved and Biologics in limbo...such is governement regulators


    Dus dit jaar wordt er nog geen goedkeuring gegeven en wordt er gewacht op een betere tijd om dit er door te krijgen? verbeter me als ik het niet goed heb
  12. [verwijderd] 12 juli 2007 16:21

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0


    Re: U.S. House fails to act on biogenerics bill:-wait till next year !
    The Political climate will be better.Election time for most of Congress.

    FDA bill approved and Biologics in limbo...such is governement regulators


  14. [verwijderd] 12 juli 2007 16:52

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    marieke2 schreef:

    Re: U.S. House fails to act on biogenerics bill:-wait till next year !
    The Political climate will be better.Election time for most of Congress.

    FDA bill approved and Biologics in limbo...such is governement regulators


    Dus dit jaar wordt er nog geen goedkeuring gegeven en wordt er gewacht op een betere tijd om dit er door te krijgen? verbeter me als ik het niet goed heb

    House voorstel bevat geen clausule voor pathway biologics met fda..
    Senaat voorstel wel..
    kans op volgend jaar
    ook kans op compromis dit jaar al

    dus valt nog niets over te zeggen
  15. [verwijderd] 12 juli 2007 16:53

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    marieke2 schreef:

    Denk niet dat de koers hier hard gaat op reageren.

    belang is in de outlook en de mensen daar
    dr allan heeft ook tijd vrijgemaakt om met enekel investeerders one on one te praten

    paar geinteresseerden daar is waar de evt jus in zit
  16. [verwijderd] 12 juli 2007 17:09

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    FredericC:

    coinstarz/mpetish geen idee
    read_this_n0w dat ben ik
    ben voor mijzelf grote houder in insm, anderen hier ongetwijfeld grotere belangen.

    heb zelf zijdelings medische achtergrond
  19. [verwijderd] 12 juli 2007 20:19

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    marieke2 schreef:

    het zakken is al begonnnen, weinig animo

    ik wacht rustig af, verkoop niets meer
    en ik indien rond 0,70 dan heb ik 2 orders staan net iets erboven en eentje eronder

    en probeer komende maand dr allan eindelijk eens te spreken te krijgen
    erg vriendelijk, jammer da tik hem 1 keer gemist heb
2.002 Posts
Pagina: «« 1 ... 38 39 40 41 42 ... 101 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.012
AB InBev 2 5.495
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.515
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.588
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.729
Aedifica 3 903
Aegon 3.258 322.686
AFC Ajax 538 7.087
Affimed NV 2 6.289
ageas 5.844 109.887
Agfa-Gevaert 14 2.049
Ahold 3.538 74.330
Air France - KLM 1.025 35.023
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.688
Allfunds Group 4 1.469
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.819
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.836 242.922
AMG 971 133.199
AMS 3 73
Amsterdam Commodities 305 6.687
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 490
Antonov 22.632 153.605
Aperam 92 14.975
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.767
Arcelor Mittal 2.033 320.656
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.293
Aroundtown SA 1 219
Arrowhead Research 5 9.729
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.089
ASML 1.766 106.412
ASR Nederland 21 4.452
ATAI Life Sciences 1 7
Atenor Group 1 485
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.647
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392